Artificial intelligence is increasingly being positioned as a strategic tool to alleviate persistent labor shortages in biotech and rare disease treatment, where limited human expertise has constrained drug discovery and therapeutic development; at the Web Summit in Qatar, executives from AI-driven companies including Insilico Medicine and GenEditBio highlighted how training large multimodal AI models and integrating AI with gene editing platforms can automate complex research tasks, identify promising drug candidates more efficiently, and expand capacity for precision therapies that human teams alone have struggled to develop quickly and at scale.
Sources
https://techcrunch.com/2026/02/06/how-ai-is-helping-with-the-labor-issue-in-treating-rare-diseases/
https://longbridge.com/en/news/275141010
https://www.findarticles.com/new-ai-platforms-tackle-rare-disease-labor-crunch/
Key Takeaways
• AI is being deployed as a force multiplier in biotech, capable of automating labor-intensive parts of drug discovery and research to help address the scarcity of trained specialists in rare disease treatment.
• Companies like Insilico Medicine are developing generalized AI models that can handle multiple drug discovery tasks simultaneously, while others are focusing on AI-enhanced gene editing and delivery systems to make novel therapies practical and more affordable.
• Despite its promise, real-world application of AI in rare disease contexts still depends on improved data availability and diversity to train predictive models that can generalize across varied biological conditions.
In-Depth
The healthcare and biotech sectors have long struggled with a fundamental bottleneck: there simply aren’t enough skilled researchers, clinicians, and technologists to tackle the vast number of rare diseases affecting millions worldwide. While traditional drug discovery and therapeutic development rely heavily on expert-driven experimentation and analysis, recent shifts toward artificial intelligence offer a compelling alternative that could amplify human effort. At the Web Summit in Qatar in early February 2026, executives from leading AI biotechnology firms outlined concrete ways in which cutting-edge AI systems are being designed to fill these gaps, reduce time-to-discovery, and open new avenues for treating diseases previously neglected due to resource constraints.
Insilico Medicine, a biotech company known for using deep learning and big data to inform molecular design, is pioneering approaches to train so-called “pharmaceutical superintelligence.” Through platforms like “MMAI Gym,” the firm aims to teach large language models to take on a range of tasks traditionally handled by specialists — from target discovery to candidate molecule generation — at scales and speeds humans cannot match. By automating hypothesis generation, pattern recognition, and high-volume data analysis, AI can help teams sift through enormous chemical and biological landscapes to spot promising therapeutic avenues that would otherwise require hundreds of highly trained researchers and years of iterative work to identify.
Other innovators are integrating AI with gene-editing technologies such as CRISPR. GenEditBio, for example, uses machine-learning models to analyze chemical structures and optimize delivery vehicles that can safely transport gene-editing tools to target cells. This fusion of AI with biological engineering is particularly important because, beyond identifying drug candidates, rare-disease treatment often depends on delivering corrective therapies directly into affected tissue — a process fraught with technical and safety challenges. By teaching AI to recognize patterns in delivery mechanisms and biological interactions, these platforms are lowering the cost, increasing success rates, and potentially transforming once-experimental techniques into scalable therapies.
Despite these advances, industry leaders acknowledge that the potential of AI will only be fully realized when it is matched with larger, more diverse datasets. AI and machine learning systems depend on quality data to learn and generalize; in rare diseases, where patient populations may be small and clinical information fragmented, gathering adequate “ground truth” data remains a challenge. There are also ongoing discussions about how to ensure AI systems remain transparent and clinically reliable as they take on more complex tasks.
Still, the consensus among developers, investors, and scientists is clear: AI won’t replace human expertise, but it will be indispensable in multiplying it. With appropriate investments in data infrastructure, regulatory frameworks, and responsible deployment, artificial intelligence could significantly accelerate the pace at which rare disease therapies are discovered and brought to patients, offering hope to millions who today face limited treatment options.